drugset / Trial / NCT00752635

Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris

NCT00752635

Phase 4 Completed 48 enrolled Johnson & Johnson Taiwan Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the effectiveness and safety of norgestimate-ethinyl estradiol as comparted with cyproterone acetate-ethinyl estradiol among female patients with moderate acne vulgaris.

Timeline

Start
2004-09
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyproterone acetate-ethinyl estradiol Unknown
Subject Ortho Tri-Cyclen LO Unknown 0.18 mg Oral
Subject Ortho Tri-Cyclen LO Unknown 0.215 mg Oral
Subject Ortho Tri-Cyclen LO Unknown 0.25 mg Oral

Indications